Inhibikase Therapeutics (IKT) Share-based Compensation (2020 - 2026)
Inhibikase Therapeutics (IKT) posted quarterly Share-based Compensation of $5.6 million for Q1 2026, up 172.24% year-over-year from $2.0 million in Q1 2025, and up 22.63% quarter-over-quarter from $4.5 million in Q4 2025.
Inhibikase Therapeutics (IKT) Share-based Compensation (2020 - 2026) Analysis & Trends
Inhibikase Therapeutics (IKT) has reported Share-based Compensation for 7 consecutive years, with $5.6 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Share-based Compensation rose 172.24% year-over-year to $5.6 million; the TTM figure through Mar 2026 stood at $18.8 million (up 85.87% YoY), while the FY2025 annual figure was $43.6 million, up 435.13% from the prior year.
- Share-based Compensation climbed to $5.6 million in Q1 2026 per IKT's latest filing, from $4.5 million in the prior quarter.
- Across five years, Share-based Compensation topped out at $7.9 million in Q4 2024 and bottomed at $30697.0 in Q2 2024.
- Historically, Share-based Compensation has averaged $1.8 million across 5 years, with a median of $129781.0 in 2023.
- Annual changes were most pronounced in 2022 — Share-based Compensation slumped 79.15% — and 2025, when it jumped 13610.6%.
- Inhibikase Therapeutics' Share-based Compensation stood at $100363.0 in 2022, then climbed by 21.81% to $122249.0 in 2023, then surged by 6369.14% to $7.9 million in 2024, then plunged by 42.67% to $4.5 million in 2025, then climbed by 22.63% to $5.6 million in 2026.
- Business Quant data shows IKT's Share-based Compensation at $5.6 million in Q1 2026, $4.5 million in Q4 2025, and $4.5 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Share-based Compensation (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 108.10 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 243.00 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 277.20 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 137.41 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 590,899.88 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 86.63 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 41.25 Mn |
| 10 | Inhibikase Therapeutics | 420.72 Mn | 261.70 Mn | - | 5.35 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 5.35 Mn |
| Jun 30, 2026 | 5.35 Mn |
| Mar 31, 2026 | 5.56 Mn |
| Mar 31, 2026 | 5.56 Mn |
| Dec 31, 2025 | 4.53 Mn |
| Dec 31, 2025 | 4.53 Mn |
| Sep 30, 2025 | 4.53 Mn |
| Sep 30, 2025 | 4.53 Mn |
| Jun 30, 2025 | 4.21 Mn |
| Jun 30, 2025 | 4.21 Mn |
| Mar 31, 2025 | 2.04 Mn |
| Mar 31, 2025 | 2.04 Mn |
| Dec 31, 2024 | 7.91 Mn |
| Dec 31, 2024 | 7.91 Mn |
| Sep 30, 2024 | 148,024.00 |
| Sep 30, 2024 | 148,024.00 |
| Jun 30, 2024 | 30,697.00 |
| Jun 30, 2024 | 30,697.00 |
| Mar 31, 2024 | 53,434.00 |
| Mar 31, 2024 | 53,434.00 |